报价延迟最少15分钟:2025/11/16 04:41 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.03 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-13.13/-0.61
|
|
企业价值
4.37M
|
| 资产负债 |
|
每股账面净值
-2.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 04:41 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |
